European Urology Oncology

Papers
(The H4-Index of European Urology Oncology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Editorial Board338
Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Blad99
Reply to Jorge Abreu-Gomez, Masoom Haider, and Sangeet Ghai’s Letter to the Editor re: Francesco Giganti, Louise Dickinson, Clement Orczyk, et al. Prostate Imaging after Focal Ablation (PI-FAB): A Pro91
Reply to Ugo Giovanni Falagario, Alberto Martini, Francesco Pellegrino, et al.’s Letter to the Editor re: Derya Tilki, Ming-Hui Chen, Jing Wu, et al. Prostate-specific Antigen Level at the Time of Sal90
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New 88
Facts and Myths About Stage Migration: Should the Will Rogers Phenomenon Ride off into the Distance?85
Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma82
Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series80
Stereotactic Magnetic Resonance–guided Adaptive Radiation Therapy for Localized Kidney Cancer: Early Outcomes from a Prospective Phase 1 Trial and Supplemental Cohort78
Early Oncological Outcomes in Patients who Underwent Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging Before Radical Prost76
Assessment of the Reporting and Incidence of Prostate Cancer Unconventional Histologies in Tertiary Referral Institutions: An Under-reported but Exploding Phenomenon?75
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer73
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant67
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies67
A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial67
Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non–muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study63
Re: Francesco Giganti, Louise Dickinson, Clement Orczyk, et al. Prostate Imaging After Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Ther60
Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients60
Re: Martino Pedrani, Alberto De Giorgi, Andrea Gallina, et al. When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era. Eur Urol Oncol. In press. http58
Patient- and Procedure-specific Risk Factors for Urinary Incontinence After Robot-assisted Radical Prostatectomy: A Nationwide, Population-based Study56
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study54
A Systematic Review of the Diagnostic Accuracy of Deep Learning Models for the Automatic Detection, Localization, and Characterization of Clinically Significant Prostate Cancer on Magnetic Resonance I53
Magnetic Resonance Imaging–guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis51
Hyperthermic Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial50
The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Stud49
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer48
Stereotactic Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer: Final Results of a Phase 2b Trial47
Epidemiology, Screening, and Prevention of Bladder Cancer45
Magnetic Resonance Imaging–Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE)45
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcom44
Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio’s Letter to the Editor re: David D’Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder 44
Contents44
Contents43
Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank43
Large Language Models in Uro-oncology42
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis41
ProCUSNet: Prostate Cancer Detection on B-mode Transrectal Ultrasound Using Artificial Intelligence for Targeting During Prostate Biopsies41
Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial41
The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort39
Utility of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Detecting Lymph Node Involvement in Comparison to Conventional Imaging in Patients with Bladder Cancer with Variant Hi39
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial39
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer39
MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses39
0.29043483734131